Research on iron regulatory erythroid factors in children with β-thalassemia

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Beta-thalassemia major (β-TM) is a severe inherited blood disorder requiring lifelong transfusion therapy.
• Iron regulation and erythropoiesis are critical in managing β-TM.
• Novel erythroid factors' roles in β-TM pathophysiology require elucidation.

Purpose of the Study:

• To compare mRNA expression of iron regulatory erythroid factors in children with β-TM.
• To investigate the relationship between these factors and transfusion requirements.
• To identify potential biomarkers for anemia severity in β-TM.

Main Methods:

• Recruited 98 children with transfusion-dependent β-TM.
• Classified children based on hemoglobin levels (≤90 g/L vs. >90 g/L).
• Utilized real-time fluorescence quantitative PCR to measure mRNA expression of FAM210B, CCDC115, HO-1, PCBP1, PCBP2, NCOA4, and Nrf2.

Main Results:

• FAM210B, HO-1, and NCOA4 mRNA levels were significantly higher in the lower hemoglobin group (p<0.05).
• Elevated FAM210B and NCOA4 expression correlated with increased transfusion needs.
• No significant differences were observed for CCDC115, PCBP1, PCBP2, and Nrf2.

Conclusions:

• FAM210B and NCOA4 may serve as indicators of erythropoiesis and anemia severity in pediatric β-TM.
• These factors warrant further investigation as potential therapeutic targets for β-TM and related disorders.